Finding a Liability-free Space in Which Personalized Medicine can Bloom
Personalized medicine uses genetic and other screening tests to predict a patient's response to specific drug and biologic therapies (together “drugs”), with the aim of choosing a treatment that will provide benefits while avoiding drug‐related harms. There are two schools of thought on how tor...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2007-10, Vol.82 (4), p.461-465 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 465 |
|---|---|
| container_issue | 4 |
| container_start_page | 461 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 82 |
| creator | Evans, B J |
| description | Personalized medicine uses genetic and other screening tests to predict a patient's response to specific drug and biologic therapies (together “drugs”), with the aim of choosing a treatment that will provide benefits while avoiding drug‐related harms. There are two schools of thought on how tort liability may affect personalized medicine, i.e., whether fear of lawsuits will tend to accelerate progress or slow it down. Tort suits include product liability suits against manufacturers and negligence suits against physicians and other providers of health‐related services.
Clinical Pharmacology & Therapeutics (2007) 82, 461–465; doi:10.1038/sj.clpt.6100335; published online 22 August 2007 |
| doi_str_mv | 10.1038/sj.clpt.6100335 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1038_sj_clpt_6100335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CPT6100335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3955-1b2bb0bb2d423fbcfa225d13ad1e26e802777242eea2ea4e04d99d0d60d61e173</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRbK2ePSl78Zh2P5Js9qjFVqFiwYrHsB8TuyXdlGyL1F9vSqI9CgvDMs87MzwIXVMypIRno7AamnKzHaaUEM6TE9SnCWdRmvDkFPUJITKSjKc9dBHCqvnGMsvOUY8KQXmcZn00nThvnf_ECs-c0q50231U1AD4baMMYOfxx9KZJZ5DHSqvSvcNFr-AdcZ5wEZ5_FBW1foSnRWqDHDV1QF6nzwuxk_R7HX6PL6fRYbLJImoZloTrZmNGS-0KRRjiaVcWQoshYwwIQSLGYBioGIgsZXSEps2jwIVfIBG7VxTVyHUUOSb2q1Vvc8pyQ9K8rDKD0ryTkmTuG0Tm51egz3ynYMGuOsAFYwqi1p548KRkzQVktGGEy335UrY_7c3H88XxxNu2qRX210Nf9Hf_g_lUYUl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Finding a Liability-free Space in Which Personalized Medicine can Bloom</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Evans, B J</creator><creatorcontrib>Evans, B J</creatorcontrib><description>Personalized medicine uses genetic and other screening tests to predict a patient's response to specific drug and biologic therapies (together “drugs”), with the aim of choosing a treatment that will provide benefits while avoiding drug‐related harms. There are two schools of thought on how tort liability may affect personalized medicine, i.e., whether fear of lawsuits will tend to accelerate progress or slow it down. Tort suits include product liability suits against manufacturers and negligence suits against physicians and other providers of health‐related services.
Clinical Pharmacology & Therapeutics (2007) 82, 461–465; doi:10.1038/sj.clpt.6100335; published online 22 August 2007</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/sj.clpt.6100335</identifier><identifier>PMID: 17713468</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>New York, NY: Nature Publishing</publisher><subject>Biological and medical sciences ; Biomarkers - analysis ; Conflict of Interest ; Drug Therapy - ethics ; Drug-Related Side Effects and Adverse Reactions ; Ethics, Clinical ; Genetic Privacy - ethics ; Genetic Privacy - legislation & jurisprudence ; Genetic Testing - ethics ; Genetic Testing - legislation & jurisprudence ; Government Regulation ; Humans ; Insurance, Health, Reimbursement - ethics ; Insurance, Health, Reimbursement - legislation & jurisprudence ; Legislation, Drug ; Liability, Legal ; Medical sciences ; Patient Selection - ethics ; Pharmacogenetics - ethics ; Pharmacogenetics - legislation & jurisprudence ; Pharmacology. Drug treatments ; United States</subject><ispartof>Clinical pharmacology and therapeutics, 2007-10, Vol.82 (4), p.461-465</ispartof><rights>2007 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3955-1b2bb0bb2d423fbcfa225d13ad1e26e802777242eea2ea4e04d99d0d60d61e173</citedby><cites>FETCH-LOGICAL-c3955-1b2bb0bb2d423fbcfa225d13ad1e26e802777242eea2ea4e04d99d0d60d61e173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fsj.clpt.6100335$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fsj.clpt.6100335$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19167921$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17713468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Evans, B J</creatorcontrib><title>Finding a Liability-free Space in Which Personalized Medicine can Bloom</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Personalized medicine uses genetic and other screening tests to predict a patient's response to specific drug and biologic therapies (together “drugs”), with the aim of choosing a treatment that will provide benefits while avoiding drug‐related harms. There are two schools of thought on how tort liability may affect personalized medicine, i.e., whether fear of lawsuits will tend to accelerate progress or slow it down. Tort suits include product liability suits against manufacturers and negligence suits against physicians and other providers of health‐related services.
Clinical Pharmacology & Therapeutics (2007) 82, 461–465; doi:10.1038/sj.clpt.6100335; published online 22 August 2007</description><subject>Biological and medical sciences</subject><subject>Biomarkers - analysis</subject><subject>Conflict of Interest</subject><subject>Drug Therapy - ethics</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Ethics, Clinical</subject><subject>Genetic Privacy - ethics</subject><subject>Genetic Privacy - legislation & jurisprudence</subject><subject>Genetic Testing - ethics</subject><subject>Genetic Testing - legislation & jurisprudence</subject><subject>Government Regulation</subject><subject>Humans</subject><subject>Insurance, Health, Reimbursement - ethics</subject><subject>Insurance, Health, Reimbursement - legislation & jurisprudence</subject><subject>Legislation, Drug</subject><subject>Liability, Legal</subject><subject>Medical sciences</subject><subject>Patient Selection - ethics</subject><subject>Pharmacogenetics - ethics</subject><subject>Pharmacogenetics - legislation & jurisprudence</subject><subject>Pharmacology. Drug treatments</subject><subject>United States</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1Lw0AQhhdRbK2ePSl78Zh2P5Js9qjFVqFiwYrHsB8TuyXdlGyL1F9vSqI9CgvDMs87MzwIXVMypIRno7AamnKzHaaUEM6TE9SnCWdRmvDkFPUJITKSjKc9dBHCqvnGMsvOUY8KQXmcZn00nThvnf_ECs-c0q50231U1AD4baMMYOfxx9KZJZ5DHSqvSvcNFr-AdcZ5wEZ5_FBW1foSnRWqDHDV1QF6nzwuxk_R7HX6PL6fRYbLJImoZloTrZmNGS-0KRRjiaVcWQoshYwwIQSLGYBioGIgsZXSEps2jwIVfIBG7VxTVyHUUOSb2q1Vvc8pyQ9K8rDKD0ryTkmTuG0Tm51egz3ynYMGuOsAFYwqi1p548KRkzQVktGGEy335UrY_7c3H88XxxNu2qRX210Nf9Hf_g_lUYUl</recordid><startdate>200710</startdate><enddate>200710</enddate><creator>Evans, B J</creator><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200710</creationdate><title>Finding a Liability-free Space in Which Personalized Medicine can Bloom</title><author>Evans, B J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3955-1b2bb0bb2d423fbcfa225d13ad1e26e802777242eea2ea4e04d99d0d60d61e173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Biological and medical sciences</topic><topic>Biomarkers - analysis</topic><topic>Conflict of Interest</topic><topic>Drug Therapy - ethics</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Ethics, Clinical</topic><topic>Genetic Privacy - ethics</topic><topic>Genetic Privacy - legislation & jurisprudence</topic><topic>Genetic Testing - ethics</topic><topic>Genetic Testing - legislation & jurisprudence</topic><topic>Government Regulation</topic><topic>Humans</topic><topic>Insurance, Health, Reimbursement - ethics</topic><topic>Insurance, Health, Reimbursement - legislation & jurisprudence</topic><topic>Legislation, Drug</topic><topic>Liability, Legal</topic><topic>Medical sciences</topic><topic>Patient Selection - ethics</topic><topic>Pharmacogenetics - ethics</topic><topic>Pharmacogenetics - legislation & jurisprudence</topic><topic>Pharmacology. Drug treatments</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Evans, B J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Evans, B J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Finding a Liability-free Space in Which Personalized Medicine can Bloom</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2007-10</date><risdate>2007</risdate><volume>82</volume><issue>4</issue><spage>461</spage><epage>465</epage><pages>461-465</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>Personalized medicine uses genetic and other screening tests to predict a patient's response to specific drug and biologic therapies (together “drugs”), with the aim of choosing a treatment that will provide benefits while avoiding drug‐related harms. There are two schools of thought on how tort liability may affect personalized medicine, i.e., whether fear of lawsuits will tend to accelerate progress or slow it down. Tort suits include product liability suits against manufacturers and negligence suits against physicians and other providers of health‐related services.
Clinical Pharmacology & Therapeutics (2007) 82, 461–465; doi:10.1038/sj.clpt.6100335; published online 22 August 2007</abstract><cop>New York, NY</cop><pub>Nature Publishing</pub><pmid>17713468</pmid><doi>10.1038/sj.clpt.6100335</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2007-10, Vol.82 (4), p.461-465 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_crossref_primary_10_1038_sj_clpt_6100335 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Biological and medical sciences Biomarkers - analysis Conflict of Interest Drug Therapy - ethics Drug-Related Side Effects and Adverse Reactions Ethics, Clinical Genetic Privacy - ethics Genetic Privacy - legislation & jurisprudence Genetic Testing - ethics Genetic Testing - legislation & jurisprudence Government Regulation Humans Insurance, Health, Reimbursement - ethics Insurance, Health, Reimbursement - legislation & jurisprudence Legislation, Drug Liability, Legal Medical sciences Patient Selection - ethics Pharmacogenetics - ethics Pharmacogenetics - legislation & jurisprudence Pharmacology. Drug treatments United States |
| title | Finding a Liability-free Space in Which Personalized Medicine can Bloom |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T16%3A32%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Finding%20a%20Liability-free%20Space%20in%20Which%20Personalized%20Medicine%20can%20Bloom&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Evans,%20B%20J&rft.date=2007-10&rft.volume=82&rft.issue=4&rft.spage=461&rft.epage=465&rft.pages=461-465&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/sj.clpt.6100335&rft_dat=%3Cwiley_cross%3ECPT6100335%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17713468&rfr_iscdi=true |